Evaluation on an introduction method of fentanyl patch by using short-acting opioid for cancer pain management in the outpatient setting.

Evaluation on an introduction method of fentanyl patch by using short-acting opioid for cancer pain management in the outpatient setting. - Evaluation on an introduction method of fentanyl patch by using short-acting opioid for cancer pain management in the outpatient setting.(Miyagi-HBPCOG 008)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005507

Enrollment

Registered

2011-04-26

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Pain

Interventions

introduction method of fentanyl patch by using short-acting opioid for cancer pain management

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer pain patients with various malignant tumors. Patient with 20 years of age or more at the date of consent agreement. Patients considered as appropriate for the treatment of opioid by investigators.

Exclusion criteria

Exclusion criteria: Patients with hypersensitivity to opioid Patients with medical history of opiod addiction Patients considered necessary for titration inpatient setting Patients with respiratory dysfunctions such as chronic lung disease Patients with asthma Patients with serious heart dysfunction Patients with serious hepatic or renal dysfunction Patients with intracranial hypertension and disturbed consciousness Patients with skin disease such as eczema and atopy at the attached site Patients with 40 degree or more fever Homeostatically Pregnant patients and patients who may possibly be pregnant. Patients treated with opioid antagonists such as pentazocine and buprenorphine within 2 days prior to fentanyl patch attachment. Patients under the age of 20 Patients considered as inappropriate for study by investigator

Design outcomes

Primary

Measure	Time frame
Pain Relief Rate	—

Secondary

Measure	Time frame
Adverse Effect Quality of life Patient Satisfaction Compliance	—

Countries

Japan

Contacts

Public ContactKei Nakagawa

Tohoku University Graduate School of Medicine Division of Integrated Surgery and Oncology

kein_h11@surg1.med.tohoku.ac.jp022-717-7205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026